Plan B and Tirzepatide: Emergency Contraception Safety Guide

Plan B and tirzepatide serve distinct medical purposes—emergency contraception and metabolic disease management—but patients taking tirzepatide may wonder whether this medication affects Plan B's effectiveness. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that slows gastric emptying, potentially impacting oral medication absorption. Plan B One-Step contains levonorgestrel, which prevents pregnancy by delaying ovulation when taken within 72 hours of unprotected intercourse. Understanding potential interactions between these medications is essential for making informed decisions about emergency contraception while managing type 2 diabetes or pursuing weight loss goals.

We offer compounded medications and Zepbound®. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. References to Wegovy®, Ozempic®, Rybelsus®, Mounjaro®, or Saxenda®, or other GLP-1 brands, are informational only. Compounded and FDA-approved medications are not interchangeable.

Understanding Plan B and Tirzepatide

Plan B One-Step is an emergency contraceptive containing levonorgestrel, a synthetic progestin that prevents pregnancy primarily by delaying or inhibiting ovulation. When taken within 72 hours of unprotected intercourse, it reduces the risk of pregnancy by approximately 75–89%, with efficacy declining as time passes. Plan B does not terminate an existing pregnancy and works most effectively when taken as soon as possible after intercourse.

Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management. Administered as a once-weekly subcutaneous injection, tirzepatide enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. In pivotal clinical trials such as SURMOUNT-1, patients lost an average of 15–22% of body weight over 72 weeks.

These medications serve entirely different therapeutic purposes—emergency contraception versus metabolic disease management—but patients taking tirzepatide may have questions about potential interactions with Plan B. Understanding how each medication works is essential for addressing concerns about contraceptive efficacy and safety. While tirzepatide affects gastrointestinal motility and metabolic processes, its impact on emergency contraception requires careful examination of pharmacological mechanisms and available clinical evidence.

Does Tirzepatide Affect Plan B Emergency Contraception?

Tirzepatide may potentially affect the absorption of oral medications, including levonorgestrel emergency contraception. The FDA prescribing information for tirzepatide (Mounjaro, Zepbound) specifically notes that it can delay gastric emptying and potentially reduce the absorption of oral medications. For oral hormonal contraceptives, the FDA recommends using a non-oral contraceptive method or adding a barrier method for 4 weeks after tirzepatide initiation and after each dose escalation.

Plan B is absorbed in the small intestine, with peak plasma concentrations typically reached within 1–2 hours. Levonorgestrel undergoes metabolism involving CYP3A4 enzymes, and certain CYP3A4 inducers (such as some anticonvulsants, rifampin, and certain antiretrovirals) can reduce its effectiveness.

While there are no specific clinical studies evaluating tirzepatide's effect on single-dose emergency contraception, the delayed gastric emptying caused by tirzepatide could theoretically affect both the rate and extent of levonorgestrel absorption. This is particularly relevant during tirzepatide initiation or dose increases when gastric emptying effects may be more pronounced.

Given these considerations, patients taking tirzepatide who need emergency contraception should be aware that:

1. A copper IUD is the most effective form of emergency contraception and is not affected by tirzepatide
2. Ulipristal acetate (ella) may be more effective than levonorgestrel up to 120 hours after unprotected intercourse, particularly for patients with higher BMI, though it is also taken orally
3. If using Plan B, take it as soon as possible after unprotected intercourse

Due to limited direct evidence, shared decision-making with a healthcare provider is important when considering emergency contraception options while on tirzepatide.

How Weight Loss Medications May Impact Contraceptive Efficacy

The relationship between body weight and emergency contraceptive efficacy has generated considerable research interest and clinical debate. Several studies have suggested that Plan B may be less effective in patients with higher body mass index (BMI), particularly those with BMI ≥30 kg/m² or body weight ≥176 pounds (80 kg). A 2011 analysis found pregnancy rates were approximately four times higher in obese women compared to normal-weight women using levonorgestrel emergency contraception.

This raises an important consideration for patients taking tirzepatide: as weight loss occurs, the effectiveness of levonorgestrel emergency contraception might theoretically change. However, this relationship remains incompletely understood, and any potential improvement in Plan B's effectiveness with weight loss is speculative without specific clinical evidence.

The American College of Obstetricians and Gynecologists (ACOG) and CDC guidance indicate that emergency contraception should not be withheld based on weight, but also note that a copper IUD is the most effective emergency contraception method regardless of BMI. Ulipristal acetate (ella) is generally more effective than levonorgestrel up to 120 hours after unprotected intercourse and may maintain better efficacy at higher BMI compared to Plan B.

Rapid weight loss itself does not directly impair contraceptive efficacy. The concern with weight relates to the volume of distribution and potentially inadequate dosing for larger body sizes, not the process of losing weight.

It's worth noting that tirzepatide-induced weight loss may affect fertility. Some patients with obesity-related anovulation may experience restored ovulation as they lose weight, potentially increasing pregnancy risk if regular contraception is not used consistently. This underscores the importance of reliable ongoing contraception rather than reliance on emergency methods.

Safe Use of Emergency Contraception While Taking Tirzepatide

Patients taking tirzepatide who need emergency contraception should consider these options:

1. Copper IUD: The most effective emergency contraception method, unaffected by tirzepatide or BMI, can be placed up to 5 days after unprotected intercourse

2. Ulipristal acetate (ella): More effective than levonorgestrel up to 120 hours after unprotected intercourse, particularly for patients with higher BMI, though as an oral medication it could potentially be affected by tirzepatide's gastric emptying effects

3. Plan B One-Step (levonorgestrel): Take one 1.5 mg tablet as soon as possible after unprotected intercourse, ideally within 24 hours and no later than 72 hours

If using Plan B, take it during a period when gastrointestinal symptoms are minimal. If vomiting occurs within 2 hours of taking Plan B (per FDA labeling), contact your healthcare provider, as you may need to repeat the dose. Taking Plan B with a small amount of food may help reduce nausea without significantly affecting absorption.

Continue taking tirzepatide as prescribed—there is no need to skip or delay your regular injection when using emergency contraception. Maintain your usual injection schedule to preserve glycemic control and weight management benefits.

Be aware that Plan B may cause temporary menstrual changes, including earlier or later periods and heavier or lighter bleeding than usual. These effects are unrelated to tirzepatide. If your period is more than one week late after taking Plan B, take a pregnancy test.

Consider more reliable ongoing contraception methods. For regular contraception while on tirzepatide, non-oral methods (IUDs, implants, injections) or adding a barrier method during the first 4 weeks after tirzepatide initiation or dose increases may be advisable, as the FDA notes tirzepatide can reduce the effectiveness of oral hormonal contraceptives.

When to Consult Your Healthcare Provider

Seek medical advice promptly if you experience any of the following situations:

• Severe or persistent vomiting within 2 hours of taking Plan B, as this may prevent adequate absorption and necessitate repeat dosing or alternative emergency contraception methods

• Missed period more than one week beyond expected timing after using Plan B, requiring pregnancy testing

• Severe abdominal pain several weeks after emergency contraception use, which could indicate ectopic pregnancy—a medical emergency

• Unusual or heavy vaginal bleeding that differs significantly from your normal menstrual pattern

Proactive consultation is recommended for:

• Frequent need for emergency contraception (more than once per cycle), indicating inadequate routine contraceptive coverage and need for more reliable methods

• Questions about contraceptive options while taking tirzepatide, particularly if you have obesity-related fertility concerns or are experiencing restored ovulation with weight loss

• Planning pregnancy while on tirzepatide, as this medication is not recommended during pregnancy and should be discontinued prior to conception attempts (discuss specific timing with your healthcare provider)

• Concerns about medication interactions with any other prescriptions or supplements you're taking alongside tirzepatide

• Interest in same-day copper IUD placement for emergency contraception, which provides both immediate protection and long-term contraception

Your healthcare provider can help establish a comprehensive reproductive health plan that accounts for your metabolic treatment, weight loss goals, and contraceptive needs. This integrated approach ensures both effective diabetes or weight management and appropriate pregnancy prevention. Don't hesitate to discuss these topics openly—coordinating care across these domains is essential for optimal health outcomes and represents standard clinical practice.

Frequently Asked Questions